This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
EMA Begins Review of Bristol Myers' (BMY) Opdivo Plus Yervoy for HCC
by Zacks Equity Research
Bristol Myers' (BMY) application seeking approval for Opdivo, in combination with Yervoy, for the indication of advanced hepatocellular carcinoma gets validation in the EU.
Ionis (IONS) Completes Enrolment for Rare Disease Drug Study
by Zacks Equity Research
Ionis' (IONS) late-stage study is evaluating zilganersen in a rare neurological disorder called Alexander disease. Top-line data from this study is expected by the end of the next year.
AstraZeneca (AZN) Stock Rises 18% YTD: Should You Buy?
by Kinjel Shah
AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge with several candidates having blockbuster potential.
Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
In the closing of the recent trading day, Astrazeneca (AZN) stood at $79.76, denoting a +1.49% change from the preceding trading day.
FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug
by Zacks Equity Research
The FDA accepts Lexicon's (LXRX) resubmission seeking approval for sotagliflozin to treat adults with type 1 diabetes. A final decision is expected by Dec 20.
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Analyst Blog Highlights Novo Nordisk, AbbVie, AstraZeneca, Air T and United-Guardian
by Zacks Equity Research
Novo Nordisk, AbbVie, AstraZeneca, Air T and United-Guardian are included in this Analyst Blog.
Top Stock Reports for Novo Nordisk, AbbVie & AstraZeneca
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), AbbVie Inc. (ABBV) and AstraZeneca PLC (AZN), as well as two micro-cap stocks, Air T, Inc. (AIRT) and United-Guardian, Inc. (UG).
Is JPMorgan Diversified Return International Equity ETF (JPIN) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JPIN
The Zacks Analyst Blog Highlights Eli Lilly, Sanofi Merck, AstraZeneca's and Roche
by Zacks Equity Research
Eli Lilly, Sanofi Merck, AstraZeneca's and Roche are included in this Analyst Blog.
AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC
by Zacks Equity Research
The European Commission approves AstraZeneca's (AZN) Tagrisso in combination with chemotherapy for first-line treatment of advanced EGFR-mutated NSCLC based on data from the phase III FLAURA2 study.
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
by Kinjel Shah
Eli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi (SNY) and Regeneron's Dupixent gets approval for COPD in Europe.
AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use
by Zacks Equity Research
The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data from the phase III DUO-E study.
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN
by Kinjel Shah
FDA rejects Merck (MRK) and AbbVie's (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.
Merck's (MRK) Lung Cancer Candidate Faces FDA Rejection
by Zacks Equity Research
The FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is based on observations made on inspection of a third-party manufacturing facility.
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
by Zacks Equity Research
Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
by Zacks Equity Research
The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
by Kinjel Shah
FDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Imfinzi.
AstraZeneca's (AZN) Truqap Gets EU Nod for Breast Cancer
by Zacks Equity Research
The European Commission approves AstraZeneca's (AZN) Truqap in combination with Faslodex for ER-positive, HER2-negative advanced or metastatic breast cancer.
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
by Zacks Equity Research
Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.
AstraZeneca's (AZN) Truqap Misses Endpoints in TNBC Study
by Zacks Equity Research
AstraZeneca's (AZN) phase III CAPItello-290 study evaluating Truqap plus chemotherapy in patients with locally advanced/metastatic triple-negative breast cancer fails to meet the dual primary endpoints.
Merck's (MRK) 21-Valent Pneumococcal Jab Gets FDA Approval
by Zacks Equity Research
Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive/V116, becomes the first PCV specifically designed for adults to be approved by the FDA.
Astrazeneca (AZN) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the most recent trading session, Astrazeneca (AZN) closed at $79.31, indicating a -0.35% shift from the previous trading day.